Neuropace Inc (NPCE) Peer Comparison

$14.41

$0.28 (1.98%)

As on 28-Aug-2026 16:22EDT

Market cap

$495 Mln

Revenue (TTM)

$99 Mln

P/E Ratio

--

P/B Ratio

40.8

Div. Yield

0 %

Edit

	Neuropace Inc (NPCE)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Market cap ($ Mln)	495	12,753	10,906	9,948	9,762
Revenue ($ Mln)	99	1,505	613	785	2,589
Net Profit ($ Mln)	-19.11	160.59	-188.05	41.54	222.40
Net Margin (%)	-19.34	10.67	-30.68	5.29	8.59
RoE (%)	-123.66	10.86	-28.10	1.97	3.04
Price to Earnings	--	79.35	--	251.81	44.47
Price-To-Book	40.84	8.41	16.38	4.86	1.26

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Neuropace Inc (NPCE)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Operating Revenue	98.84	1,504.87	612.84	785.10	2,589.30
Cost of Revenue	20.14	483.98	127.96	384.30	1,245.50
Gross Profit	77.22	942.44	393.22	347.62	1,343.60
Operating Expenses	93.78	833.56	565.37	335.50	1,108.90
Operating Profit (EBIT)	-15.08	187.34	-80.49	65.30	235.00
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-19.11	203.83	-192.83	52.15	350.40
Provision for Tax	-8.65	43.24	-4.79	10.61	128.00
Profit after Tax (Net Income)	-19.11	160.59	-188.05	41.54	222.40
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	93.19	0.00	0.00	0.00

Liabilities ($ Mln)

	Neuropace Inc (NPCE)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Shareholder's Funds	11.88	1,530.77	682.49	2,112.03	7,173.90
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	67.68	210.18	135.71	705.49	2,116.80
Current Liabilities	17.43	233.78	102.33	132.66	961.30
Total Liabilities	105.57	1,826.52	893.49	2,949.70	10,576.50

Assets ($ Mln)

	Neuropace Inc (NPCE)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Non-Current Assets	10.80	630.60	404.74	1,749.63	7,231.50
Current Assets	86.19	1,344.12	515.78	1,200.55	3,020.50
Total Assets	105.57	1,826.52	893.49	2,949.70	10,576.50
Total Debt*	69.93	212.71	102.84	690.94	1,203.70
Net Current Assets	0.00	1,110.35	413.45	1,067.90	2,059.20

Cashflow ($ Mln)

	Neuropace Inc (NPCE)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Cash From Operating Activities	-11.01	238.66	-46.34	117.42	532.20
Cash Flow from Investing Activities	-0.33	-404.59	-77.61	-298.47	-189.70
Cash from Financing Activities	19.60	26.53	11.89	-15.21	-283.20
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Neuropace Inc (NPCE)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
ROCE (%)	-25.07	11.76	-22.53	1.79	8.98
ROE (%)	-123.66	10.86	-28.10	1.97	3.04
ROA (%)	-12.47	7.95	-18.00	1.36	2.02
EBIT Margin (%)	-13.63	13.63	-30.58	9.87	-5.99
Net Margin (%)	-19.34	10.67	-30.68	5.29	8.59
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Neuropace Inc (NPCE)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Revenue Growth (%)	11.59	17.55	41.55	16.49	1.37
EBIT Growth (%)	22.36	17.49	-116.42	920.91	-131.06
Net Profit Growth (%)	26.32	8.72	-102.66	400.42	-30.32
EPS Growth (%)	31.70	8.12	-96.88	394.30	-29.66
Book Value Growth (%)	-41.09	17.33	-12.65	2.16	2.19

Valuation Ratios

	Neuropace Inc (NPCE)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Price / Earnings	-23.54	68.93	-34.59	189.42	--
Price / Book Value	40.84	8.58	9.90	4.86	--
Dividend Yield (%)	0.00	--	--	0.00	--
EV/EBITDA	-41.05	53.25	-43.50	81.02	--
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Neuropace Inc (NPCE)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Debt to Equity	0.00	0.00	0.00	0.26	0.11
Short term debt to equity ratio	0.19	0.01	0.00	0.01	0.06
Current Ratio	4.94	5.75	5.04	9.05	3.14
Quick Ratio	3.91	3.86	4.46	7.64	2.33
Interest Coverage	-2.03	157.91	-38.31	3.36	8.18

Operating Efficiency Ratios

	Neuropace Inc (NPCE)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Debtors to sales (%)	15.11	12.65	22.67	20.09	17.06
Asset Turnover	0.65	0.74	0.59	0.26	0.24
Receivable days	50.29	46.54	60.95	72.41	65.39
Inventory Days	242.88	331.92	193.84	146.53	221.09
Payable days	41.48	26.16	60.19	29.05	37.02
Cash Conversion Cycle	251.68	352.30	194.60	189.88	249.46

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly